New Delhi: Going by the results from the early-stage clinical trials of Sputnik, the Russia registered world’s first COVID-19 vaccine, there is hope. The trials show that formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days.
The results were published in ‘The Lancet’. The trials also confirmed that the vaccine induces antibody responses in all participants within 21 days, reported The New Indian Express (TNIE).
The Russian government is keen to get the vaccine tried in India as part of the phase 3 trial. It also wants Indian manufacturers to mass-produce the vaccine.
Limitations in the research
TNIE quoted researchers as saying that more research is needed to evaluate the vaccine in different populations, including older age groups, individuals with underlying medical conditions, and people in at-risk groups.
Bhubaneswar: Three vehicles reportedly got trapped after a huge electronic welcome gate installed by Khannagar…
Cuttack: Police on Friday exhumed the body of a man after his family members from…
New Delhi" The United Arab Emirates (UAE) has introduced a new visa-on-arrival policy, easing entry…
New Delhi: Alok Verma is set to become the next director in-charge of Steel Authority…
Bhubaneswar: Around 3.5 crore individuals will be benefitted from a merger of the Centre’s flagship…
Bengaluru: The Enforcement Directorate (ED) officials raided the office of Mysuru Urban Development Authority (MUDA)…
New Delhi: Amid increased geopolitical tensions, with the war in East Europe and the Middle…
Bhubaneswar: Senior Congress leader Mohammad Moqium on Friday said that the party is likely to…